We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sensus Healthcare, Inc. (SRTS) Stock Moves 1.91%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Sensus Healthcare, Inc. (SRTS - Free Report) closed at $4.80, marking a +1.91% move from the previous day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31%.
Heading into today, shares of the company had lost 2.28% over the past month, lagging the Medical sector's gain of 3.46% and the S&P 500's gain of 5.05%.
Analysts and investors alike will be keeping a close eye on the performance of Sensus Healthcare, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of $0.01, down 90% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $8.8 million, down 4.76% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.11 per share and a revenue of $41.95 million, indicating changes of -73.17% and +0.34%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Sensus Healthcare, Inc. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Sensus Healthcare, Inc. presently features a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Sensus Healthcare, Inc. is holding a Forward P/E ratio of 42.82. This valuation marks a premium compared to its industry average Forward P/E of 26.87.
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 175, this industry ranks in the bottom 29% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sensus Healthcare, Inc. (SRTS) Stock Moves 1.91%: What You Should Know
In the latest trading session, Sensus Healthcare, Inc. (SRTS - Free Report) closed at $4.80, marking a +1.91% move from the previous day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31%.
Heading into today, shares of the company had lost 2.28% over the past month, lagging the Medical sector's gain of 3.46% and the S&P 500's gain of 5.05%.
Analysts and investors alike will be keeping a close eye on the performance of Sensus Healthcare, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of $0.01, down 90% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $8.8 million, down 4.76% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.11 per share and a revenue of $41.95 million, indicating changes of -73.17% and +0.34%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Sensus Healthcare, Inc. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Sensus Healthcare, Inc. presently features a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Sensus Healthcare, Inc. is holding a Forward P/E ratio of 42.82. This valuation marks a premium compared to its industry average Forward P/E of 26.87.
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 175, this industry ranks in the bottom 29% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.